News Article | May 23, 2017
Dr. Kasra Djalayer, Board Certified Physician in Internal Medicine, Obesity Medicine, & Clinical Nutrition with Gifford Medical Center, has joined The Expert Network©, an invitation-only service for distinguished professionals. Dr. Djalayer has been chosen as a Distinguished Doctor™ based on peer reviews and ratings, numerous recognitions, and accomplishments achieved throughout his career. Dr. Djalayer outshines others in his field due to his extensive educational background, career longevity, and numerous awards and recognitions. He attended the University of Complutense in Madrid from which he graduated with his M.D. in 1989. After that, he went on to complete his residency in internal medicine at Yale University’s Griffin Hospital Prevention Research Center. He then undertook four fellowships, including one in Clinical Immunology and Rheumatology from the University of Vermont and one in School Aging and Geriatrics at Stanford University. Dr. Djalayer also holds a Ph.D. in immunology and an M.S. in Clinical Research from the University of London and has completed various post-graduate studies at Harvard University. With nearly 30 years dedicated to medicine, Dr. Djalayer brings a wealth of knowledge to his industry and, in particular, to his areas of expertise, obesity medicine, clinical nutrition, geriatrics, rheumatology, and dementia-related behavioral disorders. When asked why he decided to pursue a career in medicine, Dr. Djalayer said: "My father and grandfather were both doctors, and my father encouraged me to pursue medicine. I wanted to be a doctor because I wanted to help people, to treat them appropriately, with empathy and kindness." Dr. Djalayer is currently a primary care physician practicing with Gifford Medical Center in Randolph, Vermont and is the medical director of Rowan Court Health & Rehabilitation Center, a nursing home in Barre, Vermont. For five consecutive years, he has received both the Patient’s Choice Award and the Compassionate Doctor Recognition Award and is ranked among the top 3% of physicians in the United States. Before joining Gifford Health Care, Inc., Dr. Djalayer worked at several hospitals across New England, including Franklin Regional Hospital and New London Hospital in New Hampshire, and Brattleboro Memorial Hospital in Vermont. Today, his practice covers a vast spectrum of conditions relating to internal and adult medicine as well as rheumatic diseases. From dementia, heartburn, and immunizations, to physicals and challenges with weight loss, his sharp diagnostic abilities have earned him a reputation as one of the best physicians in the United States. Known to his patients as “Dr. DJ”, Dr. Djalayer values the importance of building strong and trusting relationships with each of his clients. He is also famous among both his patients and colleagues for having a photographic memory. Dr. Djalayer is licensed to treat patients in New Hampshire, Vermont, Connecticut, and Missouri, and works hard to provide only the highest quality of care. In 2012, Dr. Djalayer received a letter of appreciation from President Barack Obama, thanking him for his years of commitment and hard work in the healthcare field. To stay involved in his community, he frequently speaks and teaches at field seminars to help mold the next generation of medical professionals. For more information, visit Dr. Djalayer's profile on the Expert Network here: https://expertnetwork.co/members/kasra-djalayer,-md,-phd/2deff4db17af148f The Expert Network© has written this news release with approval and/or contributions from Dr. Kasra Djalayer. The Expert Network© is an invitation-only reputation management service that is dedicated to helping professionals stand out, network, and gain a competitive edge. The Expert Network selects a limited number of professionals based on their individual recognitions and history of personal excellence.
Fiocchi A.,Pediatric Hospital Bambino Gesu |
Burks W.,University of North Carolina at Chapel Hill |
Bahna S.L.,Louisiana State University Health Sciences Center |
Bielory L.,Rutgers University |
And 12 more authors.
World Allergy Organization Journal | Year: 2012
Background: Probiotic administration has been proposed for the prevention and treatment of specific allergic manifestations such as eczema, rhinitis, gastrointestinal allergy, food allergy, and asthma. However, published statements and scientific opinions disagree about the clinical usefulness. Objective: A World Allergy Organization Special Committee on Food Allergy and Nutrition review of the evidence regarding the use of probiotics for the prevention and treatment of allergy. Methods: A qualitative and narrative review of the literature on probiotic treatment of allergic disease was carried out to address the diversity and variable quality of relevant studies. This variability precluded systematization, and an expert panel group discussion method was used to evaluate the literature. In the absence of systematic reviews of treatment, meta-analyses of prevention studies were used to provide data in support of probiotic applications. Results: Despite the plethora of literature, probiotic research is still in its infancy. There is a need for basic microbiology research on the resident human microbiota. Mechanistic studies from biology, immunology, and genetics are needed before we can claim to harness the potential of immune modulatory effects of microbiota. Meanwhile, clinicians must take a step back and try to link disease state with alterations of the microbiota through well-controlled longterm studies to identify clinical indications. Conclusions: Probiotics do not have an established role in the prevention or treatment of allergy. No single probiotic supplement or class of supplements has been demonstrated to efficiently influence the course of any allergic manifestation or long-term disease or to be sufficient to do so. Further epidemiologic, immunologic, microbiologic, genetic, and clinical studies are necessary to determine whether probiotic supplements will be useful in preventing allergy. Until then, supplementation with probiotics remains empirical in allergy medicine. In the future, basic research should focus on homoeostatic studies, and clinical research should focus on preventive medicine applications, not only in allergy. Collaborations between allergo-immunologists and microbiologists in basic research and a multidisciplinary approach in clinical research are likely to be the most fruitful. Copyright © 2012 World Allergy Organization.
Schutz K.,Hannover Medical School |
Hughes R.G.,The Binding Site Group |
Parker A.,The Binding Site Group |
Quinti I.,University of Rome La Sapienza |
And 6 more authors.
Journal of Clinical Immunology | Year: 2013
Purpose A poor antibody response of IgM and IgA antibodies upon vaccination with pneumococcal polysaccharides (PnPS) is discussed as independent risk factors for bronchiectasis in patients with antibody deficiency syndrome (ADS) receiving immunoglobulin replacement therapy. However, the kinetics of the specific IgM and IgA response to vaccination with multivalent pneumococcal polysaccharides requires a more detailed knowledge. In this study we aimed i) to develop a standardised multivalent PnPS-IgM and IgA-ELISA, and ii) to compare the sensitivity of the multivalent to the serotype specific antibody response, and iii) to determine the kinetics of the anti-PnPS IgM and IgA antibodies in healthy subjects. Methods We immunised n020 healthy adults with a 23- valent PnPS vaccine (Pneumovax®). The kinetics of the 23-valent antibody response was assessed for 1 year with newly developed ELISAs for IgM and IgA isotypes, along with serotype specific responses. Results The IgA and IgM antibody response peaked at 2 and 3weeks, respectively. IgM antibody levels remained at a plateau (above 80 % of peak response) for 3 months. After one year, specific antibody levels were still at about 30 % of the peak response. The 23-valent antibody response yielded significantly higher responder rates than assessment of single serotypes. Conclusion Testing the IgM and IgA immune response to polysaccharide vaccination with a multivalent PnPS ELISA may be a feasible tool for assessment of the immune function in patient groups who receive IgG replacement therapy. © Springer Science+Business Media, LLC 2012.
PubMed | Federal University of São Paulo, Clinical Immunology and Rheumatology and Nove de Julho University
Type: Comparative Study | Journal: European annals of allergy and clinical immunology | Year: 2016
Ethnic background interferes on the prevalence of asthma among schoolchildren (4 to 9 years old, SC) born and living in So Paulo, Brazil.International Study of Asthma and Allergy in Childhood (ISAAC)s written standard and complementary questionnaires were applied to SC (similar socioeconomic status) living in the city of So Paulo: no-Japanese Brazilian (NJB, N = 306) and Japanese Brazilian (third generation, born in Brazil, from Japanese families with no miscegenation, JB, N = 258).The prevalence of current asthma was significantly higher among NJB in comparison to JB (22.2% vs 14.7%, respectively). To have rhinitis and to exercise less than once/week were risk factors for both groups of children.Although both groups were apparently exposed to the same environment, other cultural differences do not allow us to conclude about the ethnic component having greater influence than the environment in the development of asthma in these individuals.